Spain Angel Fernandez, president and managing director of MSD Spain and Portugal, covers the company´s current pipeline and portfolio strategy. He also explains how the company collaborate with a wide variety of stakeholders. What is the history of MSD in the Spanish market? Overall, MSD is a company with 127…
Cyprus Jacqueline Anastassiades has been involved in the development of the Cypriot healthcare sector for more than 10 years as the Managing Director of MSD. With the upcoming healthcare reforms, she brings her expert insights into the key requirements the Cyprus national health system should validate as well as the…
UK Peter Burema, CEO of NextPharma, explains the specificities of a UK-based CDMO with manufacturing sites on the European continent. He describes how NextPharma refocused its efforts on being a customer-centric one-stop-shop by deciding on smart investments, and why quality will always remain the key differentiation factor for a CDMO. In…
Spain The managing director of the Spanish affiliate of one of France’s most exciting and ambitious mid-caps speaks out about crafting a commercial powerhouse and efficient launch machine in oncology, and shares the secrets of deftly managing organizational change. How would you describe Ipsen´s legacy and footprint within the Spanish…
UK Laura McMullin, General Manager of the pharmaceutical division of Pierre Fabre in the UK and Ireland, explains the huge untapped potential of the organisation and her intention to make the affiliate the best performing in the coming years. She also details the strong heritage of Oncology and the affiliate’s exciting…
UK With four out of the five NHS bodies, Leeds City Region is strongly anchored in the British life sciences ecosystem. Chair of Leeds City Region Enterprise Partnership, Roger Marsh OBE, highlights what else makes the region special: its great talent, dedication to discovery and ability to build bridges between academia…
Spain Alba Ancochea of FEDER, the association that groups together Spain’s 337 rare disease patient organizations, explains how it interacts with both government and industry to the benefit of rare disease patients, the evolving situation for these patients in Spain, and her strategy for the future. Could you please start by…
UK Philip Lews Williams, managing director of the UK affiliate of French ophthalmology specialist Théa, describes the evolution of the company’s engagement in the UK and his strategy for taking on the big players in eyecare. Laboratoires Théa entered the UK for the first time back in 2007 via a joint…
UK Having just announced a major investment into a new UK Discovery Centre in London that is set to open in 2020, MSD is committed to leverage on the UK’s potential in driving forward early stage discovery. Louise Houson, Managing Director for the UK and Ireland explains the reasons for that…
R&D Portugal has forged a name for itself in terms of early adoption of new technology and ideas; making the country a prime destination for clinical trials as well as a market in which multinational pharma companies can trial innovative new treatments before rolling them out across the continent. “We are…
Turkey Murat Üçer, reputed macroeconomist, former advisor to the Ministry of Economy, Global Source Partners’ consultant in Turkey, co-founder of Turkey Data Monitor, and senior lecturer at Koç University, dissects the dynamics driving the Turkish economy as well as the main risks that lie ahead. With a GDP growth of 7.4…
UK Heading the Life Sciences strategy for Scotland’s main economic development agency Scottish Enterprise, Julia Brown recalls some of the region’s unique features making it an ideal place for life Sciences investment: a historic focus on research and interest in clinical trials, great talent from world-class universities, as well as an…
See our Cookie Privacy Policy Here